Cancer

Cover image for Vol. 123 Issue 24

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 6.072

ISI Journal Citation Reports © Ranking: 2016: 34/217 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

VIEW

  1. 1 - 100
  2. 101 - 126
  1. Original Articles

    1. Discipline

      Clinical Trials
      First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors

      Philippe L. Bédard, Michael A. Davies, Scott Kopetz, Dejan Juric, Geoffrey I. Shapiro, Jason J. Luke, Anna Spreafico, Bin Wu, Christelle Castell, Corinne Gomez, Sylvaine Cartot-Cotton, Florent Mazuir, Michel Dubar, Sandrine Micallef, Brigitte Demers and Keith T. Flaherty

      Version of Record online: 4 OCT 2017 | DOI: 10.1002/cncr.31044

      • image
      • image
      • image
      • image
      • image

      This first-in-human study evaluates the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of SAR260301, a selective inhibitor of phosphoinositide 3-kinase β. SAR260301 is well tolerated, but it cannot achieve exposure sufficient to inhibit the phosphoinositide 3-kinase pathway because of rapid clearance; therefore, its clinical development has been terminated.

    2. Disease Site

      Hematologic Malignancies
      Clinical impact of colonization with multidrug-resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia

      Sebastian Scheich, Sarah Lindner, Rosalie Koenig, Claudia Reinheimer, Thomas A. Wichelhaus, Michael Hogardt, Silke Besier, Volkhard A. J. Kempf, Johanna Kessel, Hans Martin, Anne C. Wilke, Hubert Serve, Gesine Bug and Björn Steffen

      Version of Record online: 28 SEP 2017 | DOI: 10.1002/cncr.31045

      • image
      • image
      • image

      Patients who are colonized by multidrug-resistant organisms have lower survival because of higher nonrelapse-related mortality after allogeneic hematopoietic stem cell transplantation. Mortality during severe neutropenia after transplantation does not differ between patients with and without colonization, but the period as an outpatient after transplantation seems to be most critical for fatal outcomes in colonized patients.

    3. Chest and Lung Disease
      Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature

      Rathi N. Pillai, Madhusmita Behera, Taofeek K. Owonikoko, Alice O. Kamphorst, Suchita Pakkala, Chandra P. Belani, Fadlo R. Khuri, Rafi Ahmed and Suresh S. Ramalingam

      Version of Record online: 28 SEP 2017 | DOI: 10.1002/cncr.31043

      • image

      Monoclonal antibodies against programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) are reported to be effective therapies for patients with non-small cell lung cancer. This systematic review of 5744 patients with non-small cell lung cancer treated in trials with PD-1 and PD-L1 inhibitors reports no difference between the efficacy of the 2 classes of drugs in terms of response rate or toxicity profiles.

    4. Discipline

      Clinical Trials
      Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation

      Amir T. Fathi, Traci M. Blonquist, Daniela Hernandez, Philip C. Amrein, Karen K. Ballen, Malgorzata McMasters, David E. Avigan, Robin Joyce, Emma K. Logan, Gabriela Hobbs, Andrew M. Brunner, Christelle Joseph, Ashley M. Perry, Meghan Burke, Tanya Behnan, Julia Foster, Meghan K. Bergeron, Jenna A. Moran, Aura Y. Ramos, Tina T. Som, Jessica Rae, Kaitlyn M. Fishman, Kristin L. McGregor, Christine Connolly, Donna S. Neuberg and Mark J. Levis

      Version of Record online: 28 SEP 2017 | DOI: 10.1002/cncr.31038

      • image
      • image
      • image
      • image
      • image

      Cabozantinib is well tolerated by patients with acute myeloid leukemia with a maximum tolerated dose of 40 mg daily, and it may have a unique advantage over other FMS-like tyrosine kinase 3 inhibitors in targeting the F691 tyrosine kinase domain mutation, which is increasingly being seen as a secondary resistance alteration after initial FMS-like tyrosine kinase 3 inhibitor therapy.

    5. Disease Site

      Breast Disease
      Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ

      Elizabeth Shurell, Cristina Olcese, Sujata Patil, Beryl McCormick, Kimberly J. Van Zee and Melissa L. Pilewskie

      Version of Record online: 28 SEP 2017 | DOI: 10.1002/cncr.30972

      • image
      • image

      Despite the demonstration of a clear benefit for the use of radiotherapy in patients with ductal carcinoma in situ, evidence regarding the optimal timing of adjuvant radiotherapy is lacking. The results of the current study of >1300 women indicate that, in patients with ductal carcinoma in situ undergoing breast-conserving therapy, a delay in the initiation of radiotherapy of >12 weeks is associated with a significantly increased risk of ipsilateral breast tumor recurrence.

    6. Discipline

      Disparities Research
      The Patient Protection and Affordable Care Act dependent coverage expansion: Disparities in impact among young adult oncology patients

      Elysia M. Alvarez, Theresa H. Keegan, Emily E. Johnston, Robert Haile, Lee Sanders, Paul H. Wise, Olga Saynina and Lisa J. Chamberlain

      Version of Record online: 22 SEP 2017 | DOI: 10.1002/cncr.30978

      The Patient Protection and Affordable Care Act Dependent Coverage Expansion provision increased insurance coverage, but not among all patients. Private insurance increased for white and Asian patients in higher income neighborhoods, potentially widening social disparities in private insurance coverage among young adults with cancer.

    7. Disease Site

      Gynecologic Oncology
      The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas

      Matthieu Le Gallo, Meghan L. Rudd, Mary Ellen Urick, Nancy F. Hansen, National Institutes of Health Intramural Sequencing Center Comparative Sequencing Program, Maria J. Merino, David G. Mutch, Paul J. Goodfellow, James C. Mullikin and Daphne W. Bell

      Version of Record online: 21 SEP 2017 | DOI: 10.1002/cncr.30971

      • image
      • image
      • image

      The objective of the current study was to search for novel somatically mutated genes in uterine carcinosarcomas using a combination of whole exome and targeted gene sequencing. The authors report frequent somatic frameshift mutations in forkhead box A2 (FOXA2) in uterine carcinosarcomas as well as in serous, clear cell, and endometrioid endometrial carcinomas. The findings implicate FOXA2 as a likely pathogenic driver gene in uterine carcinosarcomas and carcinomas.

    8. Discipline

      Clinical Trials
      Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases

      Kathryn C. Arbour, Mark G. Kris, Gregory J. Riely, Ai Ni, Kathryn Beal, Mariza Daras, Sara A. Hayes, Robert J. Young, Christopher R. Rodriguez, Linda Ahn, William Pao and Helena A. Yu

      Version of Record online: 21 SEP 2017 | DOI: 10.1002/cncr.30990

      • image
      • image

      Pulse/continuous-dose erlotinib produces a 74% overall response rate and a 75% response rate in brain metastases in patients with epidermal growth factor receptor (EGFR)–mutant lung cancers and untreated brain metastases who are EGFR tyrosine kinase inhibitor–naive. Central nervous system control persists even after progression elsewhere and could be useful in situations in which central nervous system control is critical.

    9. Disease Site

      Breast Disease
      Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy

      Alejandro Chaoul, Kathrin Milbury, Amy Spelman, Karen Basen-Engquist, Martica H. Hall, Qi Wei, Ya-Chen Tina Shih, Banu Arun, Vicente Valero, George H. Perkins, Gildy V. Babiera, Tenzin Wangyal, Rosalinda Engle, Carol A. Harrison, Yisheng Li and Lorenzo Cohen

      Version of Record online: 20 SEP 2017 | DOI: 10.1002/cncr.30938

      • image
      • image

      The current study examines the effects of a Tibetan yoga program versus a stretching program or usual care on sleep disturbances and fatigue in women with early breast cancer who are undergoing chemotherapy. Tibetan yoga appears to be associated with fewer daily sleep disturbances, but no group differences were noted with regard to overall sleep disturbances or fatigue. Patients who practiced Tibetan yoga at least twice weekly during the follow-up reported lower subjective and objective sleep disturbances at 3 months and 6 months after treatment compared with those who did not, and had better outcomes than those patients receiving usual care.

    10. Chest and Lung Disease
      Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study

      Dawei Yang, Xiaoju Zhang, Charles A. Powell, Jun Ni, Bin Wang, Jianya Zhang, Yafei Zhang, Lijie Wang, Zhihong Xu, Li Zhang, Guoming Wu, Yong Song, Wenhua Tian, Jia-an Hu, Yong Zhang, Jie Hu, Qunying Hong, Yuanlin Song, Jian Zhou and Chunxue Bai

      Version of Record online: 20 SEP 2017 | DOI: 10.1002/cncr.31020

      • image
      • image
      • image
      • image
      • image

      Herein, the authors developed and validated 2 novel models for the early diagnosis of lung cancer based on clinical and imaging features combined with a panel of 4 biomarkers to assist with the clinical evaluation of lung cancer risk probability. Both the patient risk model and the nodule risk model appear to demonstrate excellent discrimination, allowing for appropriate stratification of the patients with different levels of lung cancer risks.

    11. Discipline

      Survivorship
      Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: The memory & motion study

      Sheri J. Hartman, Sandahl H. Nelson, Emily Myers, Loki Natarajan, Dorothy D. Sears, Barton W. Palmer, Lauren S. Weiner, Barbara A. Parker and Ruth E. Patterson

      Version of Record online: 19 SEP 2017 | DOI: 10.1002/cncr.30987

      • image
      • image
      • image

      Breast cancer survivors randomized to an exercise arm significantly improve on an objective measure of processing speed compared with a control arm, but only among those diagnosed with breast cancer within the past 2 years. Within the exercise arm, there is a significant dose response, with greater increases in physical activity associated with greater improvements in neurocognitive testing and self-reported cognitive abilities.

    12. Neurocognitive, psychosocial, and quality-of-life outcomes in adult survivors of childhood non-Hodgkin lymphoma

      Matthew J. Ehrhardt, Daniel A. Mulrooney, Chenghong Li, Malek J. Baassiri, Kari Bjornard, John T. Sandlund, Tara M. Brinkman, I-Chan Huang, Deo Kumar Srivastava, Kirsten K. Ness, Leslie L. Robison, Melissa M. Hudson and Kevin R. Krull

      Version of Record online: 15 SEP 2017 | DOI: 10.1002/cncr.31019

      • image
      • image
      • image

      Adult survivors of childhood non-Hodgkin lymphoma experience impaired neurocognitive function, emotional distress, and poor health-related quality of life. Early-detection and intervention strategies are recommended.

    13. Pediatric Oncology
      The cost and cost-effectiveness of childhood cancer treatment in El Salvador, Central America: A report from the Childhood Cancer 2030 Network

      Soad Fuentes-Alabi, Nickhill Bhakta, Roberto Franklin Vasquez, Sumit Gupta and Susan E. Horton

      Version of Record online: 15 SEP 2017 | DOI: 10.1002/cncr.31022

      The results of the current study indicate that the treatment of patients with selected pediatric cancers in a specialized unit in El Salvador can achieve good outcomes at a cost per newly diagnosed case of US $28,707 and a cost per life saved of $58,586. This meets the World Health Organization threshold of being “very cost-effective.” Strong support from local foundations is important in making treatment affordable.

    14. Quality of Life
      Quality of life after surgery for intracranial meningioma

      Luke S. Benz, Margaret R. Wrensch, Joellen M. Schildkraut, Melissa L. Bondy, Joshua L. Warren, Joseph L. Wiemels and Elizabeth B. Claus

      Version of Record online: 13 SEP 2017 | DOI: 10.1002/cncr.30975

      Patients with meningioma experience statistically significant decreases in quality of life compared with healthy controls of similar demographic breakdown, most notably within the domains of Physical Functioning and Social Functioning, Role-Physical, Role-Emotional, and Vitality. However, these differences vary in clinical significance.

    15. Disease Site

      Genitourinary Disease
      Variation in the use of active surveillance for low-risk prostate cancer

      Björn Löppenberg, David F. Friedlander, Anna Krasnova, Andrew Tam, Jeffrey J. Leow, Paul L. Nguyen, Hawa Barry, Stuart R. Lipsitz, Mani Menon, Firas Abdollah, Jesse D. Sammon, Maxine Sun, Toni K. Choueiri, Adam S. Kibel and Quoc-Dien Trinh

      Version of Record online: 13 SEP 2017 | DOI: 10.1002/cncr.30983

      • image
      • image

      There are significant variations in surveillance rates for low-risk prostate cancer according to the facility type and between individual institutions. A significant increase in the use of active surveillance from 2010 to 2014 has been found.

    16. Discipline

      Outcomes Research
      Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis

      Tara O. Henderson, Susan K. Parsons, Kristen E. Wroblewski, Lu Chen, Fangxin Hong, Sonali M. Smith, Jennifer L. McNeer, Ranjana H. Advani, Randy D. Gascoyne, Louis S. Constine, Sandra Horning, Nancy L. Bartlett, Bijal Shah, Joseph M. Connors, John I. Leonard, Brad S. Kahl, Kara M. Kelly, Cindy L. Schwartz, Hongli Li, Jonathan W. Friedberg, Debra L. Friedman, Leo I. Gordon and Andrew M. Evens

      Version of Record online: 13 SEP 2017 | DOI: 10.1002/cncr.30979

      • image

      Adolescents and young adults with Hodgkin lymphoma treated on an adult clinical trial have inferior outcomes compared with older patients treated within the same study. Younger patients with HL appear to have better outcomes when treated on a pediatric clinical trial than similarly aged patients on an adult trial.

    17. Pediatric Oncology
      Parental distress 6 months after a pediatric cancer diagnosis in relation to family psychosocial risk at diagnosis

      Sasja A. Schepers, Simone M. Sint Nicolaas, Heleen Maurice-Stam, Lotte Haverman, Chris M. Verhaak and Martha A. Grootenhuis

      Version of Record online: 13 SEP 2017 | DOI: 10.1002/cncr.31023

      • image

      The current article demonstrates that parents of children with cancer experience significant distress 6 months after the diagnosis, and this is associated with family levels of psychosocial risk 1 month after the diagnosis.

    18. Radiation Oncology
      Safety-net versus private hospital setting for brain metastasis patients treated with radiosurgery alone: Disparities in follow-up care and outcomes

      Kevin Diao, Yanqing Sun, Stella K. Yoo, Cheng Yu, Jason C. Ye, Nicholas Trakul, Richard L. Jennelle, Paul E. Kim, Gabriel Zada, John P. Gruen and Eric L. Chang

      Version of Record online: 13 SEP 2017 | DOI: 10.1002/cncr.30984

      • image

      In a retrospective cohort study of 153 patients with brain metastases, safety-net hospital patients, in comparison with private hospital patients, received fewer total follow-up neuroimaging studies (1.5 vs 3) and had higher rates of severe neurologic symptoms (15% vs 2%), hospitalizations due to brain metastases (25% vs 7.5%), and salvage neurosurgery (17% vs 6%) after radiosurgery alone. Clinicians should consider the practice setting and patient access to follow-up care when they are deciding on the optimal strategy for the treatment of brain metastases.

    19. Survivorship
      Survivorship care planning in skin cancer: An unbiased statistical approach to identifying patterns of care-plan use

      Joseph L. Benci, Andy J. Minn, Carolyn C. Vachani, Christina Bach, Karen Arnold-Korzeniowski, Margaret K. Hampshire, James M. Metz and Christine E. Hill-Kayser

      Version of Record online: 8 SEP 2017 | DOI: 10.1002/cncr.30985

      • image
      • image
      • image
      • image
      • image

      A skin cancer patient's age at diagnosis, treatment setting, and physician type significantly influence the likelihood of receiving a survivorship care plan. Identifying these factors can allow targeted improvements in the usage of survivorship care plans in these underserved patient groups.

    20. Quality of Life
      Physical function metric over measure: An illustration with the Patient-Reported Outcomes Measurement Information System (PROMIS) and the Functional Assessment of Cancer Therapy (FACT)

      Aaron J. Kaat, Benjamin D. Schalet, Joshua Rutsohn, Roxanne E. Jensen and David Cella

      Version of Record online: 8 SEP 2017 | DOI: 10.1002/cncr.30981

      • image
      • image

      Physical function is an important patient-centered endpoint in oncology research and practice. By linking the Physical Well-Being subscale of the Functional Assessment of Cancer Therapy (FACT) questionnaire with the Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function item bank, the authors illustrate how comparative effectiveness research can be enhanced by common reporting of a physical function metric, regardless of the actual measure used.

    21. Quality of life from the perspective of the patient with acute myeloid leukemia

      Sarah A. Buckley, Diana Jimenez-Sahagun, Megan Othus, Roland B. Walter and Stephanie J. Lee

      Version of Record online: 7 SEP 2017 | DOI: 10.1002/cncr.30982

      • image

      Currently, there is no quality-of-life instrument that is specific to patients with acute myeloid leukemia, and available instruments may not be ideal for measuring the quality of life in this population. This article describes the initial development of the first such instrument, the AML-QOL.

    22. Epidemiology
      Heterogeneous impact of smoking on major salivary gland cancer according to histopathological subtype: A case-control study

      Michi Sawabe, Hidemi Ito, Taishi Takahara, Isao Oze, Daisuke Kawakita, Yasushi Yatabe, Yasuhisa Hasegawa, Shingo Murakami and Keitaro Matsuo

      Version of Record online: 7 SEP 2017 | DOI: 10.1002/cncr.30957

      Herein, the authors report that smoking appears to be associated with a significantly increased risk of major salivary gland cancers overall. Furthermore, although the impact of smoking is not obvious among cases of mucoepidermoid carcinoma, it does appear to be significant among patients with major salivary gland cancers other than mucoepidermoid carcinoma.

    23. Outcomes Research
      Trends in major upper abdominal surgery for cancer in octogenarians: Has there been a change in patient selection?

      Madalyn G. Neuwirth, Christine Bierema, Andrew J. Sinnamon, Douglas L. Fraker, Rachel R. Kelz, Robert E. Roses and Giorgos C. Karakousis

      Version of Record online: 7 SEP 2017 | DOI: 10.1002/cncr.30977

      • image
      • image
      • image
      • image
      • image
      • image

      According to a large national database, total resections for esophageal, stomach, pancreatic and liver cancers among octogenarians are increasing significantly over time, driven largely by significant increases in pancreatic and hepatic operations. These increasing trends persist after incidence adjustments for cancer within the octogenarian population along with concurrent significant decreases in mortality rates despite worsening comorbidity profiles across procedure types during the same time frame, and they are significant in that they indicate a potential paradigm shift in selection criteria for major cancer operations among the eldest patients.

    24. Clinical Trials
      Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema

      Kathleen M. Sturgeon, Renata Hackley, Anna Fornash, Lorraine T. Dean, Monica Laudermilk, Justin C. Brown, David B. Sarwer, Angela M. DeMichele, Andrea B. Troxel and Kathryn H. Schmitz

      Version of Record online: 7 SEP 2017 | DOI: 10.1002/cncr.30935

      • image
      • image
      • image

      Better representation of target populations in clinical research studies leads to more persuasive study results, and will enable providers to shape the care of survivors of breast cancer in a manner relevant to those of all ethnicities and backgrounds. The WISER Survivor Clinical Trial faced multiple recruitment challenges and used unique strategies to successfully enroll minority survivors of breast cancer into a lifestyle intervention.

    25. Survivorship
      Improvement in sexual function after ovarian cancer: Effects of sexual therapy and rehabilitation after treatment for ovarian cancer

      Sharon L. Bober, Christopher J. Recklitis, Alexis L. Michaud and Alexi A. Wright

      Version of Record online: 7 SEP 2017 | DOI: 10.1002/cncr.30976

      To address distressing, documented sexual dysfunction secondary to gynecological oncology treatment, a brief behavioral intervention has been developed and delivered to 46 ovarian cancer survivors. The results from this low-intensity intervention demonstrate significant improvements in overall sexual functioning and psychological distress at 2 and 6 months of follow-up.

    26. Disease Site

      Hepatobiliary Disease
      The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts

      Hop S. Tran Cao, Qianzi Zhang, Yvonne H. Sada, Christy Chai, Steve A. Curley and Nader N. Massarweh

      Version of Record online: 25 AUG 2017 | DOI: 10.1002/cncr.30968

      • image
      • image

      Optimal treatment strategies for patients with lymph node-positive biliary tract cancers are unclear. The current results support the role of surgical resection for the treatment of lymph node-positive intrahepatic cholangiocarcinoma and gallbladder cancers and suggest a benefit from adjuvant radiation for the latter.

VIEW

  1. 1 - 100
  2. 101 - 126

SEARCH

SEARCH BY CITATION